|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.02 USD | -0.58% |
|
-17.37% | -11.57% |
| 12/05 | Trump says US FDA Commissioner Makary is out | RE |
| 08/05 | Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says | MT |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | -.--% | -.--% | 5.52x | 1.21x | 0.79x | 2.8x | 3.17x | 201.97Cr | |
| -.--% | -.--% | -5.9x | 50.64x | 2.91x | -5.34x | -4.88x | 263.54Cr | |
| Average | 0% | 0% | -0.19x | 25.92x | 1.85x | -1.27x | -0.85x | 232.75Cr | |
| Weighted average by Cap. | 0% | 0% | -0.94x | 29.19x | 1.99x | -1.81x | -1.39x |
- Stock Market
- Equities
- SRPT Stock
- Sector Sarepta Therapeutics, Inc.
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition